Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NDV-01 in BCG-Unresponsive NMIBC
NCT07342517Phase 3Withdrawn
- Sponsor
- Relmada Therapeutics, Inc.
- Start
- Jun 2026
- Primary completion
- Jun 2027
- Modality
- Small Molecules
01
Overview
A Phase 3 trial of NDV-01 in non-muscle-invasive bladder cancer (NMIBC), sponsored by Relmada Therapeutics, Inc.. Planned start Jun 2026; status: withdrawn.
02
Drugs
NDV-01
03
Conditions
non-muscle-invasive bladder cancer (NMIBC)
Beyond the preview
Go deeper on NCT07342517.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07342517.